Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Coherus BioSciences, Inc. (NASDAQ: CHRS).

Full DD Report for CHRS

You must become a subscriber to view this report.


Recent News from (NASDAQ: CHRS)

Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences - Discovering Underlying Factors of Influence
NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu Financial, Inc. (NASDAQ:VIRT), Fate Therapeutics, Inc. (NASDAQ:FATE...
Source: GlobeNewswire
Date: December, 03 2018 07:40
Coherus' Neulasta biosimilar included in federal drug program for the poor; shares up 2%
Coherus BioSciences ( CHRS +1.9% ) inks a contract with HRSA-designated Prime Vendor Apexus, LLC  for its 304B drug pricing program that includes Neulasta biosimilar UDENYCA (pegfilgrastim-cbqv). More news on: Coherus BioSciences, Healthcare stocks news, Stocks on the move, R...
Source: SeekingAlpha
Date: November, 30 2018 10:47
Coherus BioSciences Announces Apexus Contract Agreement for 340B Hospitals and Clinics, and Q-Code Issuance from CMS
REDWOOD CITY, Calif., Nov. 30, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that the company has executed a 340B prime vendor program contract agreement with Apexus, LLC. Apexus is a recognized leader in the ambulatory hospital outpatient setting and th...
Source: GlobeNewswire
Date: November, 30 2018 09:30
FDA OKs Coherus Bio's Neulasta biosimilar shares up 7%
The FDA approves Coherus BioSciences' ( CHRS +6.8% ) UDENYCA (pegfilgrastim-cbqv), a biosimilar to Amgen's ( AMGN -2.3% ) Neulasta, the first for the company. More news on: Coherus BioSciences, Amgen Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: November, 02 2018 13:45
U.S. FDA Approves UDENYCA(TM) (pegfilgrastim-cbqv)
REDWOOD CITY, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (NASDAQ: CHRS), today announced that the U.S. Food and Drug Administration (FDA) has approved UDENYCA™ (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European ...
Source: GlobeNewswire
Date: November, 02 2018 13:41
AbbVie down 4% on Humira price cut in Europe
AbbVie ( ABBV -3.9% ) slips on more than 60% higher volume in what would be a reasonable reaction by investors following the FDA nod for Novartis' Humira biosimilar Myrimoz. More news on: AbbVie Inc., Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, Read more ... ...
Source: SeekingAlpha
Date: October, 31 2018 15:35
New Research: Key Drivers of Growth for UnitedHealth Group, The Wendy's Co., Xenia Hotels & Resorts, TopBuild, Coherus BioSciences, and Virtu Financial - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 24, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of UnitedHealth Group Incorporated (NYSE:UNH), The Wendy's Company (NASDA...
Source: GlobeNewswire
Date: October, 24 2018 09:15
Coherus BioSciences to Report Third Quarter 2018 Financial Results on November 8th
REDWOOD CITY, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS) today announced that its third quarter 2018 financial results will be released after market close on Thursday, November 8, 2018.  Starting at 4:30 p.m. ET, Coherus’ management will h...
Source: GlobeNewswire
Date: October, 22 2018 08:00
Coherus BioSciences Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that effective October 8, 2018, the compensation committee of the company’s board of directors granted 65 new employees options to purchase an aggregate of 542,000 shares...
Source: GlobeNewswire
Date: October, 09 2018 08:00
Generics in the green following proposed favorable guidance from FDA
Most generic drug firms are enjoying an uptick in buying. This morning, FDA Commissioner Scott Gottlieb, M.D., released a statement on preliminary guidance aimed at making the review process for generic drug applications more efficient. More news on: Aceto Corporation, Aclaris Therapeutics...
Source: SeekingAlpha
Date: October, 02 2018 14:03

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-1816.2015.9516.2015.70422,858
2018-05-1716.2015.9516.2015.70422,858
2017-06-1214.1515.72515.87514.057,378,129
2017-06-0922.9520.6523.159120.55773,891
2017-06-0820.6522.7023.2420.651,061,591

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1192,382215,40342.8880Short
2018-12-1026,38875,12235.1269Short
2018-12-0725,15138,00766.1747Short
2018-12-0679,577252,25731.5460Cover
2018-12-0466,196104,96263.0666Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CHRS.


About Coherus BioSciences, Inc. (NASDAQ: CHRS)

Logo for Coherus BioSciences, Inc. (NASDAQ: CHRS)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: CHRS)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 15 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 10 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 10 2018
      Pre-effective amendment to an S-3 filing
      Filing Type: S-3/AFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 03 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 13 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 13 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018

       

       


      Daily Technical Chart for (NASDAQ: CHRS)

      Daily Technical Chart for (NASDAQ: CHRS)


      Stay tuned for daily updates and more on (NASDAQ: CHRS)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: CHRS)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CHRS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CHRS and does not buy, sell, or trade any shares of CHRS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/